Italy: clinical trials of Novartis approved by AIFA 2017, by stage
This statistic depicts the share of clinical trials funded by Novartis approved by AIFA (Italian Pharmaceutical Agency) in Italy in 2017, by stage. According to data, the largest percentage of clinical studies approved by AIFA were in the second stage (37.3 percent), whereas only 2.3 percent of trials were conducted in the fourth stage.